Proprotein convertase subtilisin/kexin type 9 inhibitors: prospects for cholesterol-lowering therapy in type 2 diabetes
Diabetic dyslipoproteinemia (DLP), characterized by quantitative, qualitative, and kinetic changes in all major circulating lipids, contributes to an increased risk of atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus (DM). Inhibition of proprotein convertase subtilisi...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaslavsky O.Yu.
2023-03-01
|
| Series: | Mìžnarodnij Endokrinologìčnij Žurnal |
| Subjects: | |
| Online Access: | https://iej.zaslavsky.com.ua/index.php/journal/article/view/1242 |